17 documents

Read All
22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim...
Read More
19:52 , Oct 13, 2017 |  BC Week In Review  |  Company News

AbbVie acquires options to Turnstone immunotherapies

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
Read More
22:18 , Oct 10, 2017 |  BC Extra  |  Company News

AbbVie, Turnstone in oncolytic virus deal

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the company’s Ad- MG1-MAGEA3 . By combining oncolytic viruses with cancer vaccines, Turnstone...
Read More
23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
Read More
20:05 , May 19, 2017 |  BC Week In Review  |  Clinical News

Turnstone begins Phase I/II NSCLC trial of viral therapy

Turnstone Biologics Inc. (Ottawa, Ontario) began the Phase I/II Sandpiper trial of its adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 (MG1-MAGEA3) plus Keytruda pembrolizumab to treat metastatic non-small cell lung cancer (NSCLC)...
Read More
00:42 , Dec 31, 2016 |  BioCentury  |  Finance

Versant’s capstone

Versant Ventures ’ sixth fund, which closed at $400 million on Dec. 30, places a capstone on a five-year transformation from a traditional, diversified West Coast healthcare VC to an international therapeutics-focused investor with an...
Read More
02:27 , Nov 5, 2016 |  BioCentury  |  Finance

Turbocharging Turnstone

Turnstone Biologics Inc. ’s $41.4 million series B round provides enough runway to ramp up the company’s clinical program and run four Phase I/II trials over the next three years. OrbiMed Advisors led last week’s...
Read More
23:23 , Nov 3, 2016 |  BC Week In Review  |  Financial News

Turnstone completes venture financing

Turnstone Biologics raised $41.4 million in a series B round from OrbiMed, F-Prime Capital Partners, FACIT and Versant Ventures . Turnstone Biologics Inc. , Toronto, Ontario ...
Read More
22:55 , Nov 2, 2016 |  BC Extra  |  Financial News

Turnstone raises $41.4 million series B round

Turnstone Biologics Inc. (Toronto, Ontario) raised $41.4 million in a series B round led by new investor OrbiMed. First-time investor F-Prime Capital Partners and existing investors FACIT and Versant Ventures also participated. President and CEO...
Read More
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
Read More